We are live on
!
Find out more
FM
Frazier Management Portfolio holdings
AUM
$1.12M
1-Year Est. Return
151.58%
This Fund
S&P 500
This Quarter
Est. Return
-4.68%
1 Year Est. Return
+151.58%
3 Year Est. Return
+408.4%
5 Year Est. Return
+1,802.6%
10 Year Est. Return
–
AUM
$1.08B
AUM Growth
-$162M
(-13%)
Cap. Flow
-$69.4M
Cap. Flow
% of AUM
-6.4%
Top 10 Holdings %
Top 10 Hldgs %
77.96%
Holding
37
New
2
Increased
1
Reduced
8
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Iovance Biotherapeutics
IOVA
|
+$21.4M |
| 2 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
+$17.6M |
| 3 |
AUTL
Autolus Therapeutics
AUTL
|
+$14.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arcutis Biotherapeutics
ARQT
|
+$59.4M |
| 2 |
Tarsus Pharmaceuticals
TARS
|
+$15.6M |
| 3 |
ADVM
Adverum Biotechnologies
ADVM
|
+$14.2M |
| 4 |
Krystal Biotech
KRYS
|
+$7.48M |
| 5 |
Aclaris Therapeutics
ACRS
|
+$7.39M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.61% |
| 2 | Miscellaneous | 1.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Scholar Rock
SRRK
$7.22B
| $4.51M | 0.42% |
156,000
| – | – |
|
|
FRLN
27
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
| $4.48M | 0.41% |
36,667
| – | – |
|
|
ALNA
28
DELISTED
Allena Pharmaceuticals
ALNA
| $4.33M | 0.4% |
3,330,373
| – | – |
|
|
BLU
29
DELISTED
BELLUS Health Inc.
BLU
| $4.03M | 0.37% |
1,296,743
| – | – |
|
|
SRRA
30
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $3.95M | 0.36% |
202,803
| – | – |
|
|
AVDL
31
DELISTED
Avadel Pharmaceuticals
AVDL
| $3.89M | 0.36% |
578,104
| – | – |
|
32
Immunovant
IMVT
$9.05B
| $2.69M | 0.25% |
254,000
-254,000
| -50% | -$3.55M |
|
|
GRTX
33
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
| $2.37M | 0.22% |
241,000
| – | – |
|
|
NBRV
34
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
| $575K | 0.05% |
17,026
| – | – |
|
|
ADVM
35
DELISTED
Adverum Biotechnologies
ADVM
| – | – |
-143,703
| Closed | -$14.2M |
|
36
Cardiff Oncology
CRDF
$76.7M
| – | – |
-293,500
| Closed | -$2.72M |
|
|
ITRM
37
DELISTED
Iterum Therapeutics
ITRM
| – | – |
-102,554
| Closed | -$2.17M |
|
Similar funds
ACMV
FRCMI
DB
NAM
AP
ID
CI
DIF
Frazier Management's Q2 2021 Portfolio in Review
As of Q2 2021, Frazier Management held 37 positions worth $1.08B, down 13% from $1.25B the previous quarter. Its ten largest holdings account for 78% of the portfolio.
Frazier Management withdrew a net $69.4M in Q2 2021, closing 3 positions and reducing 8 holdings. Its most notable exit was Adverum Biotechnologies, an estimated $14.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Miscellaneous.
Against the trend, Frazier Management opened a new position in Chinook Therapeutics, Inc. Common Stock worth $15.5M.
- Frazier Management's largest Q2 2021 buy was Chinook Therapeutics, Inc. Common Stock: 1,100,000 shares worth $15.5M.
- Frazier Management added most to Iovance Biotherapeutics in Q2 2021, an estimated $21.4M increase.
- Frazier Management's biggest Q2 2021 reduction was Arcutis Biotherapeutics, cutting an estimated $59.4M.
- Frazier Management fully exited Adverum Biotechnologies in Q2 2021, selling an estimated $14.2M.
- Frazier Management's ten largest holdings make up 78% of its $1.08B portfolio in Q2 2021.
- Frazier Management opened 2 new positions and closed 3 in Q2 2021.
- Frazier Management's portfolio value fell 13% quarter-over-quarter to $1.08B.
Based on Frazier Management's 13F filing for Q2 2021, filed 11 Aug 2021.